Dunhill Financial’s Beam Therapeutics BEAM Stock Holding History

Dunhill Financial’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.8K	Sell	75 -1	-1%	-$28	﹤0.01%	830
2025 Q4	$2.1K	Buy	76 +2	+3%	+$51	﹤0.01%	731
2025 Q3	$1.8K	Hold	74	–	–	﹤0.01%	709
2025 Q2	$1.26K	Hold	74	–	–	﹤0.01%	747
2025 Q1	$1.45K	Hold	74	–	–	﹤0.01%	782
2024 Q4	$1.83K	Hold	74	–	–	﹤0.01%	717
2024 Q3	$1.81K	Hold	74	–	–	﹤0.01%	732
2024 Q2	$1.73K	Hold	74	–	–	﹤0.01%	590
2024 Q1	$2.44K	Hold	74	–	–	﹤0.01%	452
2023 Q4	$2.01K	Buy	+74	New	+$1.84K	﹤0.01%	455

Other funds holding BEAM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Dunhill Financial's BEAM Position: Q1 2026 in Review

Dunhill Financial reduced its Beam Therapeutics (BEAM) stake by 1.3% in Q1 2026, selling an estimated $28 and leaving 75 shares worth $1.8K. The position accounts for ﹤0.01% of the portfolio, ranked #830.

Dunhill Financial first reported a position in BEAM in Q4 2023 and has held it in 10 quarters since. The position peaked at $2.44K in Q1 2024. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.

Dunhill Financial held 75 shares of Beam Therapeutics worth $1.8K as of Q1 2026.
Dunhill Financial sold 1 Beam Therapeutics share in Q1 2026, an estimated $28.
Beam Therapeutics made up ﹤0.01% of Dunhill Financial's portfolio in Q1 2026, its #830 holding.
Dunhill Financial first reported a position in Beam Therapeutics in Q4 2023 and has held it in 10 quarters since.
Dunhill Financial's Beam Therapeutics position peaked at $2.44K in Q1 2024.
251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.

Based on Dunhill Financial's 13F filing for Q1 2026, filed 6 May 2026.